Sep 272017
 

By Talent4Boards Team

Talent4Boards - Great Talent builds Great Boards

– UK, Stevenage – NeRRe Therapeutics, which is developing a unique portfolio of neurokinin (NK)-1 receptor antagonists for the treatment of common debilitating conditions caused by neuronal hypersensitivity, has appointed Andrew Kay as Chairman of the Board.… => Read more

NeRRe Therapeutics appointed Andrew Kay to its Board of Directors as Chairman

From:: NeRRe Therapeutics appointed Andrew Kay to its Board of Directors as Chairman

Sorry, the comment form is closed at this time.

%d bloggers like this: